tirzepatide court ruling today Compounded GLP-1 Drugs: Texas Judge Denies PI Motion and Request for Stay of FDA's Declaration that Shortage is Resolved; Plaintiff OFA Appeals Lilly Wins Court Battle Against

Changes in dietary habits and body composition were also documented in our study, in line with previous studies

Johnson LP, et al

Targeting these vulnerabilities aims to: Inhibit pathogenic effector cells Promote pro-resolution circuits Synergize with biologics & JAK inhibitors for control Strategic opportunity Portfolios spanning IL-17 inhibitors for psoriasis, IL-13 blockers for AD, JAK inhibitors for alopecia areata, and GLP-1 receptor agonists for obesity enable smart trials pairing targeted immunology with metabolic interventions tracking: Skin endpoints: PASI/EASI Systemic endpoints: HbA1c, adipokines Stratification: BMI/IR for personalized care Bottom line To move beyond symptom control, disrupt the metabolic fuel that sustains the inflammatory cascade

Once patients reach their target weight and transition to maintenance dosing, lean body mass becomes relatively stable if protein intake and exercise continue

Garvey, W

Our bodies cant make any of the B-complex vitamins naturally, so we have to get them from what we eat